InMed Pharmaceuticals Inc. announced the Company has entered into a service contract (the Contract) with Brio Financial Group (Brio) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3033 USD | -3.71% | +2.85% | -27.09% |
05-14 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
05-14 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.09% | 1.84M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- INM Stock
- News InMed Pharmaceuticals Inc.
- InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer